SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform

Cell Chemical Biology
John M HatcherNathanael S Gray

Abstract

The SRPK family of kinases regulates pre-mRNA splicing by phosphorylating serine/arginine (SR)-rich splicing factors, signals splicing control in response to extracellular stimuli, and contributes to tumorigenesis, suggesting that these splicing kinases are potential therapeutic targets. Here, we report the development of the first irreversible SRPK inhibitor, SRPKIN-1, which is also the first kinase inhibitor that forms a covalent bond with a tyrosine phenol group in the ATP-binding pocket. Kinome-wide profiling demonstrates its selectivity for SRPK1/2, and SRPKIN-1 attenuates SR protein phosphorylation at submicromolar concentrations. Vascular endothelial growth factor (VEGF) is a known target for SRPK-regulated splicing and, relative to the first-generation SRPK inhibitor SRPIN340 or small interfering RNA-mediated SRPK knockdown, SRPKIN-1 is more potent in converting the pro-angiogenic VEGF-A165a to the anti-angiogenic VEGF-A165b isoform and in blocking laser-induced neovascularization in a murine retinal model. These findings encourage further development of SRPK inhibitors for treatment of age-related macular degeneration.

Citations

Sep 27, 2019·Nature Reviews. Drug Discovery·Joana DesterroMaria Carmo-Fonseca
Nov 2, 2019·Oncotarget·Esmee KoedootSylvia E Le Dévédec
Jun 21, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Sean M Cascarina, Eric D Ross
Jul 17, 2020·Cancer Reports·Pongphol PrattapongTavan Janvilisri
Jul 16, 2020·International Journal of Molecular Sciences·Daniela CaccamoMaria Teresa Sciortino
Apr 28, 2019·International Journal of Molecular Sciences·Elizabeth Bowler, Sebastian Oltean
Apr 19, 2020·Nature Reviews. Clinical Oncology·Sophie C BonnalJuan Valcárcel
Apr 1, 2020·Chemical Society Reviews·Ayah AbdeldayemPatrick T Gunning
Dec 5, 2020·Future Medicinal Chemistry·Elena De Vita
Dec 9, 2020·Journal of Experimental & Clinical Cancer Research : CR·Anna Di MatteoClaudia Ghigna
Dec 3, 2020·International Journal of Molecular Sciences·Cláudia BessaVânia Gonçalves
Jan 23, 2021·RSC Medicinal Chemistry·Lyn H Jones, Jeffery W Kelly
Feb 20, 2021·Journal of Experimental & Clinical Cancer Research : CR·Hongda LiuYunfei Xu
Feb 25, 2021·Signal Transduction and Targeted Therapy·Yuanjiao ZhangYe Yang
Apr 4, 2021·Cancers·Meet PatelNeelu Puri
Jun 1, 2021·Epigenetics : Official Journal of the DNA Methylation Society·I Gede Putu SupadmanabaElisa Giovannetti
May 18, 2020·Biochemical Pharmacology·Beatrice Eymin
Jun 3, 2021·International Journal of Molecular Sciences·Maxime BlijlevensVictor W van Beusechem
Jul 25, 2021·Nature Communications·Masahiko AjiroMasatoshi Hagiwara
Jan 22, 2020·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Raoni Pais SiqueiraGustavo Costa Bressan
Aug 24, 2018·Toxicology and Applied Pharmacology·Gabriela Alves MoreiraGustavo Costa Bressan
Mar 20, 2020·ACS Chemical Biology·Robert E BoerJohn S Schneekloth
Jun 20, 2020·ACS Medicinal Chemistry Letters·Mingxing TengNathanael S Gray
Sep 4, 2021·Journal of Medicinal Chemistry·Ricardo A M SerafimMatthias Gehringer
Oct 22, 2021·The Journal of Biological Chemistry·Sean R KundingerNicholas T Seyfried

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.